Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial

Autor:	Carl J. Fichtenbaum, Jonathan Z. Li, Susan L. Koletar, Amesika N. Nyaku, Jonathan Colasanti, Baiba Berzins, Carlee Moser, Constance A. Benson, Vincent C. Marconi, Babafemi Taiwo, Timothy J. Wilkin, Paul E. Sax, Edward P. Acosta
Rok vydání:	2017
Předmět:	Adult 0301 basic medicine Microbiology (medical) Pediatrics medicine.medical_specialty Anti-HIV Agents Pyridones 030106 microbiology Human immunodeficiency virus (HIV) HIV Infections Pilot Projects Drug resistance medicine.disease_cause Drug Administration Schedule Piperazines law.invention 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Maintenance therapy Randomized controlled trial law Drug Resistance Viral Oxazines medicine Humans 030212 general & internal medicine business.industry Lamivudine Clinical trial VIROLOGIC FAILURE Infectious Diseases chemistry Dolutegravir HIV-1 Brief Reports business Heterocyclic Compounds 3-Ring medicine.drug
Zdroj:	Clinical Infectious Diseases. 66:1794-1797
ISSN:	1537-6591 1058-4838
Popis:	In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy. There was no emergence of drug resistance in the participant who experienced virologic failure while receiving dolutegravir plus lamivudine. Clinical Trials Registration {"type":"clinical-trial","attrs":{"text":"NCT02263326","term_id":"NCT02263326"}}NCT02263326
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6551a91a72a197a9abbdb86ac8cf6eb7 https://doi.org/10.1093/cid/cix1131 Zobrazit plný text záznamu